STOCK TITAN

Mannkind Corporation (MNKD) 10-K Filings

MNKD NASDAQ

Here are the 10-K annual reports from Mannkind Corporation (MNKD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow MNKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNKD filings page.

Rhea-AI Summary

MannKind Corporation is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, aiming to offer patient‑centric drug–device therapies for chronic conditions.

The company currently commercializes three cardiometabolic products: Afrezza inhaled insulin for adults with diabetes, Furoscix for edema in heart failure and chronic kidney disease, and the V‑Go wearable insulin delivery device. It also earns royalties and manufacturing revenue from Tyvaso DPI for pulmonary hypertension, marketed by United Therapeutics, and recently expanded this collaboration to include MNKD‑1501.

MannKind’s pipeline includes MNKD‑201, an inhaled nintedanib for idiopathic pulmonary fibrosis now in Phase 1b and global Phase 2 studies, and MNKD‑701, an early bumetanide inhalation program. Key 2026 regulatory milestones include FDA decisions on an Afrezza pediatric sBLA by May 29, 2026 and a Furoscix ReadyFlow Autoinjector sNDA by July 26, 2026.

Manufacturing is centered in Danbury, Connecticut, where Technosphere powders, inhalers and Tyvaso DPI are produced; V‑Go and many Furoscix components are made by contract manufacturers, including in China. A 2025 FDA inspection of the Connecticut facility concluded without Form 483 observations.

The filing highlights extensive risks, including dependence on United Therapeutics’ continued emphasis on Tyvaso DPI—particularly in light of its newly promoted Tresmi soft‑mist treprostinil candidate—manufacturing and supply‑chain concentration, pricing and reimbursement pressures, evolving U.S. healthcare and privacy laws, and the need for additional capital and successful commercialization to support ongoing operations and growth.